Stoke Therapeutics, INC

Stoke Therapeutics has filed a prospectus supplement to offer up to $200 million in common stock through an at-the-market offering.

Stoke Therapeutics reported Q2 2026 financial results, detailing advancements in its Phase 3 EMPEROR study for zorevunersen in Dravet syndrome and its Phase 1 OSPREY study for STK-002 in ADOA, supported by a robust cash runway.

Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome, with a data readout anticipated in Q3 2027.

Stoke Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class I directors and the ratification of its independent auditor.

Stoke Therapeutics reported Q1 2026 financial results, highlighting positive 4-year data for zorevunersen in Dravet syndrome and providing updates on Phase 3 enrollment.

Stoke Therapeutics announced the appointment of Dr. Clare Kahn to its Board of Directors, bringing extensive experience in drug development and regulatory strategy.

Stoke Therapeutics reported a net loss of $61.6 million for Q2 2026, with revenue down significantly year-over-year, while advancing its zorevunersen and STK-002 programs.

Stoke Therapeutics reported a significant revenue increase driven by its Biogen collaboration and positive clinical progress for zorevunersen in Dravet syndrome, extending its cash runway to mid-2028.

Stoke Therapeutics reported a significant net income for the first half of 2025, driven by a major collaboration with Biogen, while advancing its clinical programs for Dravet syndrome and ADOA.

Stoke Therapeutics' Q1 2025 results showcase a significant revenue surge due to a new collaboration with Biogen, offsetting previous operating losses.

Stoke Therapeutics' Q3 2024 results show increased revenue from the Acadia collaboration, but continued net losses as the company advances its clinical programs.

Stoke Therapeutics reports a net loss of $25.7 million for the second quarter of 2024, alongside a revenue increase driven by its collaboration with Acadia Pharmaceuticals.

Stoke Therapeutics' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical development programs, including zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).

Stoke Therapeutics provides a detailed overview of its capital stock, anti-takeover provisions, and clinical development programs in its latest 10-K filing.

Seth Loring Harrison, a Director of Stoke Therapeutics, Inc., reported multiple transactions in common stock on July 16, 2026.

Thomas Mccauley, Chief Scientific Officer of Stoke Therapeutics, Inc., received 225,000 shares of common stock on July 15, 2026.

Stoke Therapeutics Chief Medical Officer Barry Ticho sold a total of 7,228 shares of common stock in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics General Counsel & Corp Sec, Jonathan Allan, reported a sale of 1,457 common shares on June 16, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Arthur Tzianabos was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Director Julie Smith was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Stoke Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 3, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Stoke Therapeutics has scheduled its annual stockholder meeting for June 3, 2025, outlining proposals including the election of directors, ratification of the auditor, and executive compensation.

Stoke Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 3, 2025, outlining proposals for director elections, auditor ratification, and executive compensation.

Stoke Therapeutics has scheduled its annual shareholder meeting for June 5, 2024, with key proposals including the election of Class II directors and ratification of KPMG LLP as the independent auditor.

Stoke Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to elect directors and ratify the appointment of its independent auditor.

A group of reporting persons, including Blue Horizon Enterprise Ltd, has reduced its beneficial ownership in Stoke Therapeutics, Inc. to below the 5% threshold following a significant share sale.

A group of reporting entities, including Ezbon International Ltd, has reduced its beneficial ownership in Stoke Therapeutics, Inc. to 6% after Ezbon sold 650,000 shares at $11.00 per share.

Ezbon International Ltd., a reporting person, has significantly reduced its stake in Stoke Therapeutics, Inc. by selling 3 million shares in an open market transaction.

Lynx1 Capital Management LP has reported an 8.1% beneficial ownership stake in Stoke Therapeutics, Inc. as of March 31, 2026.

Redmile Group, LLC and Jeremy C. Green have filed an amendment to their Schedule 13G, reporting a 6.7% beneficial ownership stake in Stoke Therapeutics, Inc.

The Toronto-Dominion Bank and its subsidiary TD Securities Inc. have reported beneficial ownership of 5.4% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 9.9% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 5.2% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a 9.8% beneficial ownership stake in Stoke Therapeutics Inc. as of December 31, 2025.